Published in Cancer Weekly, December 28th, 2004
ImClone Systems is developing two investigational antibodies, IMC-18F1 and IMC-1121B, designed to target two forms of VEGFR.
IMC-1121B is a fully human monoclonal antibody that is designed to bind to the vascular endothelial growth factor receptor-2 (VEGFR-2 or KDR) found on tumor vasculature, thereby inhibiting certain ligands...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.